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Abstract: Successful homing of drugs to the desired biological compartment of the host usually depends on the in-
trinsic properties of the drug molecules. However, it can always be manipulated by appropriate designing of the car-
rier/delivery system, as little can be done to influence the target and its surroundings. Various carrier systems have
emerged to deliver drugs to macrophages, albeit the efficacy, reliability and selectivity of these carriers are still in
question. To date, the most extensively studied carriers are liposomes and microspheres. In fact, physicochemical
properties of these carriers can alter their efficacy and specificity to a great extent. These properties include hydro-
philicity, surface charge, composition, concentration, and presence of.various target specific ligands on their sur-
face. Incidentally, the particulate nature of these vehicles may facilitate passive homing of the entrapped drug
molecules to the macrophages, which may harbour many of the important pathogens in their intracellular compart-
ments, such asMycobacteriumsps,Leishmania nd dengue virus etc., belonging to three different major classes of
microbes. Moreover, macrophages upon interaction with particulate drug delivery vehicles may act as secondary
drug depot, thus helping in localized delivery of the drug at the infected site. In the present article, a comprehensive
rt:view of literature is presented on the suitability of some lipid-based and polymeric materials as vehicles in deliv-
ery of drugs to macrophages in parasitic infections.
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1. INTRODUCTION
Designand development of potential carriers for cell spe-
.:ificdelivery01therapeutics are immensely dependent on the
:'::~~l:"ityof the carner to the cellular receptors distributed
\ anably at both the intracellular compartments and the sur-
faceof the cellular systems. Other crucial factors include the
anatOmicaland pathological barriers that hav.eto be circum-
vented,en route betore access to the recognition sites. Most
of the drugs introduced to clinical medicine exert their phar-
macologicalaction by interactive crosstalk with cell mem-
brJne through concentration- dependent reversible interac-
t:ons with specific receptor, or active sites of crucial meta-
b0iic enzymes. Obviously, to obtain a desirable therapeutic
response,the optimum amount Of the drug should be trans-
ported and delivered to the site of action with subsequent
control of drug input rate. The distribution of administered
drug to other tissues therefore seems unnecessary, wasteful
and potential cause of toxicity. Keeping into consideration
the innate toxicity and undesirable manifestations that are
.::ommonfeaturesof the available medicaments, last few dec-
ades havewitnessed tremendous advancements in the field of
controlled and targeted delivery of pharmacologically active
th~rapeuticagents. In this regard, the cell related biological
events occurring in high order of specificity and precision,
offer basis tor quantitative targeted drug delivery.
Selective drug delivery or targeting seeks to improve
upon the benefit versus risk ratio associated with the thera-
,,~'.i!ICagents. Ideally, a drug intended for clinical use should
. ddress correspondence to this author at the Central Drug Research
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have a high therapeutic index, which is a ratio of drugeffi-
cacy (therapeuticeffect) and drug toxicity (untoward effects).
The drug delivery technology has certainly infused new in-
terest in seemingly traditionally old drugs by providing
them new bio-distribution pattern with the help of novel
drug delivery system. In general, targeted drug delivery can
be achieved by using carrier systems, where reliance is placed
by exploiting both, intrinsic pathways that these drug carri-
ers follow, and bioprotection that can be ofTeredto the thera-
peuticmoleculesduringtransit through variousbodyc m-
partments. This led to conclusion that desired pharmacologi-
cal action of the administered drug is required at the desired
site only. In this regard, mononuclear cells of the host can
play important role in effective delivery of the therapeutic
agents, provided drug molecules are delivered as particulate
carrier/delivery system. The carrier-mediated delivery be-
comes more pertinent in situations when these cells provide
shelter to certain intracellular organisms. In normal course,
ingested microorganisms are killed by the lysosomal con-
tents that are released into the phagosomes. Some microor-
ganisms however can survive and multiply within the
macrophages. These intracellular pathogens includeListeria
monocytogens,..Salmonella typhyimurium, Neisseria gonor-
rhoeae, Mycobacter.iumavium, Mycobacterium tuberculosis,
mycobacterium leprae, Brucella abortus, Leishmania spp.
and Candida albicans [1-3].
In order to eliminate pathogens that find shelter inside
the macrophages, it is essential to deliver active drug mole-
cules inside these cells. Since these cells scavenge and de-
stroy most of the foreign particulate material that enters the
body, it is always advantageous to deliver the chemothera~
peutic agents to the macrophages by encapsulating them in a
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biodegradable particulate material. Such a delivery would not
only help in concentrating the drug into these cells but
should also result in controlled intracellular drug release.
Various lipid and polymeric calTiers,such as liposomes and
microspheres, have been used for delivery of drugs to the
macrophages[1-5].In the presentarticlewe have attempted
to review the application of these carriers in selective drug
delivery to these cells. However, for better understanding of
the macrophage-liposome (or microsphere) interactions, we
considered it necessary to first briefly describe the origin and
properties of the mononuclear phagocytic system.
2. MONONUCLEAR PHAGOCYTIC SYSTEM
The macrophages as well as other related cells, such as
monocyte, promonocyte, and monoblast, have been reported
to originate from a common progenitor, called the granulo-
cyte-macrophages colony-forming cells. Monoblasts, the
least mature cells of the mononuclear phagocyte system,
firstly differentiate into monocytes that remain in the bone
malTowfor 24 h and subsequently appear in the peripheral
blood. From the peripheral blood, monocytes migrate to the
extravascular tissue where they differentiate into macrophages
[6]. In fact, macrophages occupy all possible places of the
body that can be accessed from outside, thus they are found
in the liver (kupffer cells), lungs (alveolar-interstitial macro-
phages), spleen, lymph nodes, thymus, gut, malTo\\",brain,
connective tissue and serous ca\'ities [7]. They scavenge for-
eign substances as well as those materials or cells that have
undergone significant changes in their native phenotype.
Moreover, they also play a critically prominent role in host
defense against many infectious agents of bacterial, viral,
protozoal and parasitic origin. Upon invasion of microorgan-
isms, as a first line of defense, various chemotactic cytokines
(chemokines) send signals for accumulation of the mononu-
clear cells, such as monocytes and macrophages, at the site
of pathogen attack. Besides, chemokines, a variety of other
substances, including bacterial components and endotoxins,
complement components, immune complexes, etc. can also
attract macrophages. These cells may then phagocytose and
kill the infectious agents by a variety of mechanisms [8]. In
addition to the physical killing/elimination of the accumu-
lated foreign substances or microbes, macrophages can acti-
vate immune system of the host as well [9]. In fact besides
the dendritic cells and B lymphocytes, macrophages also
playa central role in activation of the host's immune system.
Moreover, tumour mass can also be infiltrated by the macro-
phages where they form an important mechanism of host
defense against tumour cells, either by inhibiting the tumour
cell division or killing the cells following secretion of solu-
ble mediators or by other means [10,11]. Macrophages can
also synthesize a large number of other substances involved
in functions of diverse nature [12]. The secreted molecules
might induce acute phase response [13], regulate haema-
topoiesis [14], help in cleansing and healing of injured tissue
[15] and regulate the homeostasis [16]. Some of the mole-
cules expressed in macrophages are supposed to be involved
in regulation of atherosclerosis, diseases affecting nervous
system or certain autoimmune disorders [17,18]. Interest-
ingly, a variety of infectious diseases originating from facul-
tative or obligate intracellular parasites rely on the
intracellular parasitism as a strategy to defer immune on-
slaught [1-3].
Although, normally in the resting state, macrophages are
activated by a range of stimuli in the course of their interac-
tion with foreign substances. Phagocytosis of foreign sub-
stances(cf Antigen) serves as an initial activating stimulus.
In natural course, macrophages are activated by cytokines
released by T helper cells, or by the molecules that are either
secretedor are integral components of the external surface of
the microbes. Among various potent activators of the macro-
phages, interferon gamma (IFN-y) secreted by activated TH
cells, and tuftsin. a split tetra peptide from a leucophilic
IgG. are the major ones.
Activatedmacrophages are moreeffective than the resting
cells in eliminating the potential pathogens, because of their
increased ability to kill the ingested microbes. In fact activa-
tion of macrophages is usually accompanied with an in-
creased secretion of inflammatory mediators, and an in-
creased ability to activate T cells. In addition, activated
macrophagesbut not the resting cells, express various cyto-
toxic proteins that help them in eliminating a broad range of
pathogens, including virus-infected cells, tumour cells and
intracellular bacteria. Activated macrophages also express
higher levels of class II MHC molecules, allowing them to
functionmore effectively as antigen-presenting cells. In fact,
macrophages and THcells during the immune response facili-
tate each other's activation.
Macrophages are capable of ingesting exogenous anti-
gens, such as whole microorganisms and insoluble particles,
and endogenous matters, such as injured or dead host cells,
cellular debris, and activated clotting factors. In the first step
in phagocytosis, macrophages are attracted by and move to-
wards a variety of substances generated in an immune re-
sponse; this process is called chemotaxis. The next step in
phagocytosis involves adherence of the antigen to the macro-
phage cell membrane. Complex antigens, such as whole bac-
terial cells or viral particles, tend to adhere well and are read-
ily phagocytosed, whereas isolated proteins and encapsulated
bacteria tend to adhere poorly and are less readily phagocyto-
sed. Adherence induces membrane protrusions, called pseu-
dopodia, to extend around the attached material. Fusion of
the pseudopodia encloses the material within a membrane-
bounded structure called phagosome, which upon entering
the endocytic processing pathway, moves towards the cell
interior, where it fuses with a lysosome to form a
phagolysosome. Lysosomes basically are a collection of
lysozyme and various other hydrolytic enzymes, which di-
gest the ingested substances. The digested contents of the
phagolysosome are then eliminated in a process called exocy-
tosis.
The macrophage membrane has been reported to possess
repertoire of receptors including those for Fc region of the
antibodyand certaincomplementfactors. Incidentally,both
of which also bind to antigen. If an antigen (e.g., a bacte-
rium) is coated with. an appropriate antibody or complement
factor, it binds more readily to the macrophages membrane;
as a result, phagocytosis is enhanced. The process by which
particularantigens are rendered more susceptible to phagocy-
tosis is called opsonization.
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3. ANTIMICROBIAL ACTIVITY OF MONONUC-
LEAR PHAGOCYTES
A number of antimicrobial and cytotoxic substances pro-
duced by activated macrophages can destroy phagocytosed
microorganisms. Many of the mediators of cytotoxicity are
reactive forms of oxygen. In fact, macrophages are known to
produce various reactive oxygen and reactive nitrogen inter-
mediates that have potent antimicrobial activity. For exam-
ple, phagocytosis is usually followed by a respiratory burst
that playa major role in killing of the pathogens. This proc-
ess results in the activation of a membrane-bound oxidase
that catalyses the reduction of oxygen to superoxide anion, a
reactive oxygen intermediate that is extremely toxic to the
ingested microorganisms. The superoxide anionalsoge er-
ates other powerful oxidizing agents, including hydroxyl
radicals and hydrogen peroxide. As the lysosome fuses with
the phagosome, and the activity of the myeloperoxidase pro-
duces hypochlorite, the active agent of the household bleach,
which is toxic to the ingested microbes.
A range of substances can activate macrophages. For ex-
ample, bacterial cell-wall components, such as lipopolysac-
charide (LPS) or muramyl dipeptide (MDP), together with a
T-cell-derived cytokine (lFN-)') or split tetrapeptide product
of IgG known as tuftsin, can upregulate expression of nitric
oxide synthetase (NOS), an enzyme that oxidizes L-arginine
to L-citrulline and nitric oxide (NO), which have potent an-
timicrobial activity. The nitric oxide yields potent antimi-
crobial substances in combination with the superoxide anion.
Recent evidences suggest that much of the antimicrobial
activity of the macrophages against bacterial, fungal, helmin-
thic, and protozoal pathogens is due to nitric oxide and sub-
stances derived from it.
Interestingly, macrophages can execute killing of the or-
ganisms in non-oxygen dependent manner as well. In fact,
they can synthesize various hydrolytic ezymes which can
hydrolyse a range of biological molecules without active
involvement of oxygen. In addition, activated macrophages
can also produce cysteine rich cationic peptides known as
defensins; the molecules that contain six invariant cysteines,
form a circular structure which is stabilized by the in-
tramolecular disulphide bonds. The circularized defensin
peptides have been shown to form ion-permeable channels in
bacterial cell membranes, the feature that helps these peptides
to kill a variety of bacteria, includingStaphylococcus
aureus, Streptococcus pneumoniae, Escheri-chia coli, Pseu-
domonas aerugenosa and Haemophilus influenzae.Acti-
vated macrophages also secrete tumour necrosis factor a
(TNF-a), a cytokine that has a variety of effects and is cyto-
toxic to some tumour cells.
4. DRUG HOMING TO MONONUCLEAR PHAGO-
CYTES
Amongst the two most widely acclaimed delivery sys-
tems, viz. microspheres and liposomes that may specifically
deliver entrapped,material to macrophages, liposomes have
been documented as microscopic vesicles composed of phos-
pholipid bilayers surrounding aqueous compartments. The
details of the preparation methods of liposomes and their
characteristics are described elsewhere [19,20]. Liposomes
have been used extensively as drug carriers, and their poten-
tial applications in cancer chemotherapy, enzyme therapy,
immuno-modulation, antimicrobial therapy, metal detoxifi-
cation, diagnostics, and topical therapy have been reviewed
elsewhere [20-24].
. Inj cting drugs encapsulated in liposomes always have an
advantage as being colloidal in nature they are recognized as
foreign particles and can readily be taken up by the phago-
cytic 'cells (cf. macrophages) and consequently, rapidly ac-
cumulate in the mononuclear phagocyte system (MPS). The
inherent tendency of the liposomes to concentrate in MPS
can be exploited to enhance the non-specific host defense
gai st various intracellular pathogens by entrapping chemo-
tactic or immunomodulatory molecules in them besides us-
ing them as carriers of antibiotics against various intracellu-
lar infections. Liposomal systems have been optimistically
cons dered as "magic bullets" for more than three decades.
Drug delivery with liposomes as a carrier system provides
options and opportunities for designing bio-stable and/or site
specific drug therapy. The engineered or tailored versions of
liposomes that offer potential of exquisite levels of target
specificity are of major concern these days. Depending on the
site of targeting, liposomes may be modified by either graft-
ing chemotactic ligands, such as peptides, polysaccharidesor
affinity ligands like antibodies, on the liposomes surface
directly or by coating their surfacewith polyethylene glycol
[25-27].
For treatment of diseases with lymphatic involvement it
is desirable to develop approaches to deliver diagnostic.
therapeutic and immunol11odulatoryagents to the lymph
nodes [28-30]. Liposomes carrying saccharides on their sur-
face showed enhanced absorption from the injection site and
also an enhanced lymph node uptake compared to the control
liposomes [31]. Further, liposomes coated with the non-
specific human antibodies upon injecting subcutaneously
exhibited a modestly increased lymphatic absorption and
lymph node uptake, compared to liposomes without the an-
tibody [32]. Moreover, an administration of anti-HLA-DR
immunoliposomes resulted into their 3-fold higher accumu-
lation in regional lymph nodes, as compared to the conven-
tional liposomes [33]. Furthermore, polyethylene glycol
(PEG) coated liposomes were found to avoid uptake by the
lymphatic system as compared to the plain liposomes
[34,35]. This apart, a novel method to enhance the lymph
node uptake of biotin coated liposomes has been explored
recently [36].
It has been shown that PS-exposure on the cell surface
serves as a signal for triggering recognition by the macro-
phages [37]. Also the macrophages have been shown to
phagocytose the large size liposomes more efficiently than'
the smaller ones [38]. In addition, grafting of the tetrapeptide
tuftsin on the liposomes surface would enable the liposomes
not only in homing the liposomised drug to the macro-
phages but also it would stimulate these cells non-
specifically against infections [39-44].
An lysis of the intracellular trafficking patterns of the
liposomal antigens reveals that after being phagocytosed by
the macrophages, liposomal antigen readily escapes from the
endosomes into the cytoplasm of the macrophages [45].
Moreover, liposomes made up of lipids with fusogenic prop-
erties have been shown to deliver their entrapped molecules
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in the cytosol of the target cells more efficiently than the
conventional forms of liposomes. On the other hand, the
membrane lipid composition of microorganisms exhibits a
great majority of anionic phospholipids that play a pivotal
role in membrane-membrane fusion [46]. As a result,
liposomes derived from the membrane lipids of various mi-
croorganisms have been used for targeting to macrophages as
well as dendritic cells [47-50). Recently, it has been demon-
strated that antigens entrapped in liposomes made up of lip-
ids fromE. coliand edible yeast generate a strong humoral
as well as cell-mediated immune responses [51-53]. Moreo-
ver, sterically stabilized liposomes have been found to pos-
sess increased stability and play major role in CD8' T-cell
response upon their targeting to the mature as well as imma-
ture dendritic cells. In a more recent study, PorA, a major
antigen ofNeisseria meningitidis,was purified and reconsti-
tuted in different types of liposomes, such as the liposomes
having mannose or phosphatidylserine on their surface for
targeting to dendritic cells (DCs). The use of targeted PorA
liposomes resulted in an improved uptake by and activation
of dendritic cells and also in an increased localization in the
draining lymph nodes [54].
The complex interaction of liposomes with phagocytic
cells is described in different steps that include stable adsorp-
tion to the cell surface, cellular uptake of intact vesicles by
an energy-dependentmechanism and lysosomal degradation
of the liposomes and their contents. Liposome adsorption to
the cell surface seems to be the rate limiting step, since it
can be assumed that stably adsorbed vesicles are more sus-
ceptible to subsequent uptake than the vesicles that are
loosely attached with the cell surface. Several prerequisites
have to be successfuIly met that eventually enable liposomes
to deliver biologically active agents to the macrophages: (1)
Jiposomes must readily bind to and be phagocytosed by 1Tee
and fixed phagocytes, (II) they must prevent degradation of
the entrapped drug, (Ill) they must retain the encapsulated
agent for delivery to the intracellular compartment of the
RES cells, and (IV) they must localize to the macrophages in
organs where metastasis or macrophage-associated disorders
occur [22].
In general, liposomes are the most widely studied carrier
used for macrophage-specific drug delivery. However, the
extent of the liposomes binding and subsequent ingestion by
macrophages depends on a number of features of the lipid
vesicles. These include composition, type, size and surface
properties of liposomes. For example, negatively charged
liposomes associate more effectively and deliver their content
more efficiently to the macrophages than the neutral
liposomes [55-58]. Similarly, smaller liposomes deliver
drugs more effectively than larger one; presumably due to
their efficient internalisation [59]. Further, it has been shown
that positively charged [60] and large sized liposomes [61]
can improve the liposome uptake, as compared to their coun-
terparts.
Systematic evaluation of multi lamellar vesicles (MLV)
with different phospholipid composition reveals that certain
classes of phospholipids are recognized preferentially by the
macrophages [35,37]. Fo!' example, inclusion of the nega-
tively charged phospholipids, such as phosphatidylserine
(PS), phosphatidylglycerol in MLV consisting of phosphati-
dylc oline (PC), greatly enhances their binding to and
phagocytosis by the macrophages. In contrast, neutral MLVs
composed exclusively of PC are internalized by these cells
with significantly lesser efficiency. In addition, it was ob-
served that liposome uptake increased linearly with the incu-
bation time and concentration. Higher uptake was observed
with maller and negatively charged liposomes. And inclu-
sion of increasing amounts of cholesterol and sphingomyelin
resulted in a decreaseduptake in the macrophages [55-58).
The efficacyof the liposomal drug formulation is influ-
enced also by the melting phase transition temperature of the
liposomal phospholipids [62,63]. Thus, encapsulation of
ampicillin in liposomes prepared from distearoylphosphati-
dyl-choline (DSPC), and dipalmitoylphosphatidylglycerol
(DPPG) resulted in delayed intracellular killing ofL. mono-
cytogenes,as compared to the liposomes composed of cho-
lesterol, unsaturated phosphatidyl cholines and phosphatidyl
serines. Like the lipid composition, the lamellarity and size
of the liposomes may also affect significantly the efficacy of
the encapsulated agents [64]. This apart, polyethylene glycol-
coated liposomes, known as stealth liposomes, are not read-
ily taken up by the macrophages in the reticuloendothelial
sys em and thus, stay in the circulation for relatively longer
peri ds of time [65-67]. In addition, incorporation of differ-
ent polymers into liposomes has been shown to enhance the
h lf-life of the liposomes in blood circulation in a concentra-.
tion-dependent manner [67]. On the other hand, grafting of
ome specific peptides on the liposomes surface has been
reported to significantly enhance their uptake by the macro-
phages, and also the anti-microbial activity of these cells
[68,69].
Macrophages possess a number of receptors, such as Fe
receptors and receptors for complements, fibronectin, lipo-
protein, mannosyl, galactosyl and many other ligands [6).
These macrophage surface receptors regulate various macro-
phage activities, such as activation, recognition, endocytosis,
secretion etc. A useful approach for promoting the uptake of
liposomal content by the macrophages is to incorporate on
the liposomes surface the ligands that can interact with the
macrophage surface receptors [70]. Numerous investigators
have shown that uptake of the ligand-incorporated liposomes
is significantly higher than the ligand-free liposomes [71-
77]. For example, incorporation of neoglycoprotein or the
ligands that contain terminal mannosyl residues on the
liposomes surface leads to their selective uptake by the
m crophages [77-79]. Similarly, liposomes composed of
ma nosylated myo-inositol (extracted from the cell wall of
microorganisms) have been shown to be preferentially taken
up by the peritoneal macrophages [78]. Further, bothin vitro
andin vivouptakes of the liposomes have been shown to
significantly increase in the macrophages by targeting (the
liposomes) through Fc surface receptors [79-81].
The incidences of the life-threatening fungal infections,
over the last several years, have dramatically increased par-
ticularly among cancer, diabetic, and immunocompromised
patients [82]. This may, however, partly be attributed to the
advancement in the field of medical sciences that have made
possible the improved recognition and diagnosis of thefun-
gal i f ctions. Besides the prolonged survival of the patients
with defects in their defense mechanisms, more invasive
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surgical procedures, development of resistarit strains to cur-
rently available anti-fungal drugs, and the increased number
of patients contracting AIDS are some of the reasons that
provide ample opportunities to the opportunistic fungi for
their establishment, leading to the full blown disease. The
emergence of fungi as clinically important pathogen has been
well documented, although their role in pathogenesis of hu-
man infection has only recently been appreciated [82,83].
Various antifungal chemotherapeutic agents available
include polyenes, azoles, allylamines, morpholines, flucyto-
sine, griseofulvin, iodides, hydroxy stibamine and imidazole
classes of drugs [84,85]. However, the drug of choice for
most systemic mycosis is a polyene antibiotic amphotericin
B (Amp-B) that interacts with ergosterol present in the fun-
gal cell membranes, creating transmembrane channels which
permit the escape of vital ions and meta-bolites. In spite of
its promising antifungal properties, the drug had limited use
due to its systemic toxicity. The efforts for reducing toxic
side effects of Amp-B by its chemical derivatization have
remained elusive [86].
Reports from many groups demonstrate that liposome
encapsulated Amp-B is effective against drug-sensitive as
well as resistant fungal infections, e.g. aspergillosis, can-
didiasis, cryptococcosis, histoplasmosis and fusarium infec-
tions [39-41]. Further, it has been shown that incorporation
of Amp-B in liposomes successfully reduces Amp-B nephro-
toxicity, which results in improved therapeutic index [39].
Following the promising clinical results, three formulations
containing Amp-B (Abelcet, Amphocil and AmBisome) are
currently-availablefor human use [87].
Keeping into consideration the fact that cell mediated
immune response involving activation of the mononuclear
phagocytes by sensitized T-cells play a key role to control
fungal infections [88]. treatment with antifungal drugs along
with the agents that provoke macrophagesimonocytes may
have an advantage. That this indeed is the case has been
demonstrated by the considerably high efficacy against sys-
temic fungal infections of Amp-B encapsulated in the
liposomes that contained tuftsin on their surface [39]. This
Amp-B formulation (Tuft-lip-Amp-B) was effective against
not only the sensitive but also the resistant strains ofCan-
dida albicans[41]. An evaluation of the effect of lipos-
omised tuftsin on T-cell proliferation as well as antibody
production reveals that tuftsin by itself elicits a strong im-
munopotentiating effect besides homing the liposomes to
macrophages. Pre-treatment with tuftsin bearing liposomes
prior to challenging the animals with drug-resistant C.albi-
canshas been shown to render the animals resistant to the
infection [41].
Nystatin encapsulated in tuftsin bearing liposomes has
been evaluated for its potential use against isolates of C.
albicansshowing lesser susceptibility to Amp-B [89]. Al-
though the liposomised 1\mp B in higher doses was found
to be effective in elimination of less susceptible strain of C.
albicansin BALB/c mice, but it cannot be recommended
due to toxicity constraints. However, liposomal nystatin at a
dose of 5mglkg was shown to possess higher efficacy (sur-
vival 40 %), compared to Amp B, and could thus be used
for treatment of drug-resistant C.albicansinfections. In ad-
dition, nystatin encapsulated in tuftsin bearing liposomes
has recently been evaluated against candidiasis in cylophos-
phamide-treatedneutropenic BALB/c mice. The role of tuft-
sin in the activation and maturation of leukocytes was ana-
lysed by treating the animals with tuftsin after cyclophos-
phamide injection. A single peritoneal injection of tuftsin
(50 Ilg/animal) for three consecutive days, significantly in-
creasedthe numbers of leukocytes in the treated animals, as
compared to the animals that did not receive such injections
[41]. The neutropenic mice on challenging with C.albicans
followed by treatment with nystatin loaded tuftsin bearing
liposomes showed increased survival, as compared to Amp-
B administered after its encapsulation in tuftsin-containing
liposomes in identical conditions.
Besides the fungal infections, liposomisation also en-
hances anti-bacterialefficacy of some of the chemotherapeutic
agents. For example, encapsulation of streptomycin, isoni-
azid and rifampicin in liposomes has been shown to increase
their efficacy againstMycobacterium tuberculosis[90,91].
Further, the antimycobacterial activity of liposomised rifam-
picin has been demonstrated to considerably increase upon
grafting tuftsin on the surface of liposomes containing ri-
fampicin [92]. Moreover, other aminoglycoside classes of
antimycobacterial drugs, such as amikacin and gentarnycin,
have also been shown to efficiently control mycobacterial
infections after their encapsulation in liposomes. SinceMy-
cobacteriumsps are intracellular pathogens, the higher effi-
cacy of antituberculardrugs can be directly correlated to the
liposome mediated passive delivery of drug molecules to the
macrophages.
Leishmaniais a protozoan parasite which causes visceral,
cutaneous, mucocutaneous and diffuse cutaneous types of
leishmaniasis in humans. Amongst these, the most devastat-
ing clinical form, visceral leishmaniasis (Kala-azar), is
caused byLeishmania donovani,which if left untreated is
usually fatal. The major front line drugs available for treat-
ment of this disease are usually very toxic, and to some of
which, such as antimoniates, the parasite has developed re-
sistance due to their indiscriminate use. It has, therefore,
become essential to develop alternate strategies to combat
this infection. Interestingly, some of the antifungal drugs
like griseofulvin, Amp Band 5-fluorocytosine have been
shown to exhibit an enhanced efficacy against leishmaniasis
when used in the liposomal form [93].
Since Leishmaniaparasite, primarily colonizes the
ononuclear macrophages, antiparasitic activity of an-
tileishmanial drugs is expected to significantly increase by
their encapsulation in liposomes. As a matter of fact, the
very first use of liposomal drugs in treatment of infectious
diseases was made in case ofLeishmaniaonly. It has been
shown that liposomised antimoniates are 700-1800 times
more effective thanthe free drug in controlling leishmaniasis'
[93]. Recently, antimonials entrapped in liposomes contain-
ing the negatively charged lipid, phosphatidylserine, which
is known to selectively interact with the macrophage surface
scavenger receptors, have been reported to have considerably
higher efficacy, as compared to other liposomal formulations
[94]. Further, Hamycin encapsulated in mannose coated
liposomes has been used in treatment of the experimental
leishmaniasis in hamsters [95]. Apart from this, primaquine-
loaded liposomes after grafting a chemotactic peptide on
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their surface have been reported to be quite effective against
experimental leishmaniasis [68]. Such peptide-grafted
liposomes were found to be rapidly cleared iTom the blood
circulation (half-life -2 min) and taken up by the cells of the
reticuloendothelial system. Furthermore, doxorubicin encap-
sulated in parasite-specific antibody coupled liposomes has
been used successfully against visceral leishmaniasis in
BALB/c mice [96]. Besides, antileishmanial efficacy of
liposomised sodium stibogluconate has been shown to fur-
ther increase (up to 200 times) by grafting tuftsin on the
liposomes surface [44].
In our recent studies, we examined chemotherapeutic effi-
cacy of Amp-B after its encapsulation in tuftsin-iTeeas well
as tuftsin bearing liposomes againstL. donovaniinfections
that were resistant to the conventional chemotherapy with
antimonials [97]. The antileishmanial activity of Amp-B was
significantly increased (P < 0.05) upon delivering Amp B in
tuftsin free liposomes. This activity was further increased (P
< 0.05) by co-administration of liposomised Amp-B with
tuftsin. These results clearly suggested that efficacy of the
various antileishmanial drugs can be substantially improved
by their delivery in liposomes and that the macrophage-
activation by immunomodulators, like tuftsin, may signifi-
cantly improve the activity of the liposomised drug prepara-
tions. In addition to tuftsin, uptake of liposomes by the
macrophages can also be enhanced by incorporation of fi-
bronectin or galactosyl residues on the liposomes surface
[98-I00].
Beside the liposomes. nanoparticles and microspheres
have also been extensively examined for their use as carriers
for delivering drugs to the macrophages. They may be po-
lymeric-biodegradableor nondegradable and proteinaceous in
nature. The term microsphere, is defined as a spherical parti-
cle with size range varying from 50 nm to 2 urn, containing
a coresubstance. Microspheres are monolithic or matrix-type
microparticles. In contrast to microspheres, nanoparticles are
in the size ranging between 10 and 1000 nm. Nanoparticles
are collective names for nanospheres and nanocapsules. The
former have a matrix structure, drug or tracers may be ad-
sorbed at their surface, entrapped in the particle or dissolved.
The latter have a polymeric shell and inner liquid core.
Preparation and characterization techniques of these particu-
late carriershave been reviewed extensively [101-104].
In a manner similar to liposomes, size, surface property,
composition, concentration, and hydrophilicity or lipophilic-
ity of microspheres and nanoparticles play a significant role
in their uptake by macrophages [105]. The events of phago-
cytosis include contact with pseudopods of macrophages
followed by their engulftnent into the cytoplasm by lamel-
lipods [106]. Hydrophobic and relatively large microspheres
are more susceptible to phagocytosis than their hydrophilic
counterparts. Likewisely, nanoparticles with lipophilic coat-
ing are taken up by macrophages more readily as compared
to their hydrophilic counterparts. The extent of phagocytosis
can be improved by coating the particle surface with opsonic
materials and activating macrophages with various activating
factors. Incubation time and dose of the vehicles can also
control the process of phagocytosis.
The influence of surface charge and size of microspheres
on their phagocytosis by mouse peritoneal macrophages were
studied by using polystyrene and phenylated poly-acrolein
microspheres of different diameter as well as modified cellu-
lose microspheres with different surface charge [107]. It was
f und that efficiency of uptake was maximum when size
range of microsphere was of the order of I-211m. For both
negatively and positively charged particles, the extent of
phagocytosis was increased with increasing zeta potentials,
and was the lowest when zeta potential was zero [108]. How-
ever, there was no significant difference in the phagocytosis
between the cationic and anionic surfaces when compared at a
zeta potential of the same absolute value. Modified cellulose
microspheres were allowed to incubate with macrophages in
order to study the influence of the hydrophobicity on macro-
phage phagocytosis. Hydrophobic microspheres prepared
from benzoyl cellulose were the most susceptible to phago-
cytosis and the non-ionic hydrophilic one was the least. It
was observed that an optimal surface hydrophobicity is nec-
essary for the microspheres to be phagocytosed [109].
Similarly, nanoparticles made from polyalkylcyanoacry-
late, polymethylmethacrylate, and human serum albumin
microspheres have been used to study the influence of vari-
ous parameters that can regulate uptake by human macro-
phages. The incorporation of lipophilic polymethylmethacry-
late in nano particles was found to result in better phagocy-
tosis, when compared with polyalkylcyanoacrylate nanoparti-
cles of similar size range [109]. Polybutylcyanoacrylate
nanoparticles coated with lipophilic Pluronic F68, a bio-
compatible poloxamer, increased phagocytosis by nearly
50%, while Pluronic FI08 had no influence. Nanoparticles
of the same material were phagocytosed to a larger extent if
they were of larger diameter. For example, phagocytosis of
nanoparticles made from human serum albumin of 1.511min
diameter was higher than that of 200 nm in diameter. Re-
cently, it has been found that polyethylene glycoldistearate
incorporated microspheres can modify the extent of the
phagocytosis depending on the concentration of the excipient
used [110]. It seems that microsphere association or uptake
by macrophages might be a saturable process [111]. For a
given cell density, uptake of particles into macrophages was
also dose-dependent. The most avid uptake was observed
with a microsphere dose of I mg/I, however, there was a
gradual reduction in the uptake as microsphere dose was in-
creased further [111].
In a manner that is typical of particulate delivery system,
coating of microspheres with opsonic materials and am-
phiphiles can modify significantly the extent of phagocytosis
by macrophages depending on the state of macrophage acti-
vation. Several proteins such as gamma-globulin, human
fibronectin, bovine tuftsin, and gelatin enhance the phagocy-
tosis, while bovine serum albumin reduce the phagocytosis
of cellulose microspheres [112]. It was also observed that the
presence of fetal calf serum increases the phagocytosis of
gelatin-grafted cellulose microspheres, while showing no
affect on other protein grafted-microspheres. The influence of
cross-linking and concentration of gelatin microspheres on
the phagocytosis by mouse peritoneal macrophages have also
been studied. Gluteraldehyde mediated cross linking of gela-
tin microspheres was found to facilitate interferon targeting
to macrophages [113]. The study showed that phagocytosis
of microspheres decreased with decreasing concentration of
latin and glutaraldehyde, and was proportionalt the
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dlIlount01mJcr~1sphcr?';3added, until a saturation of phagocy-
tosis was observed at higher doses of microspneres. It was
also demonstrated that precoating or surface immobilization
with gelatin was the most effective method to enhance the
phagocytosis among all other opsonic proteins. Phagocytic
uptake of polystyrene microspheres, coated with a series of
perfluoroalkylated amphiphiles derived from phosphocholine
and polyethylene glycol, was studied in the presence or ab-
sence of serum and peritoneal macrophages were used as
phagocytic cells [1]4]. Phagocytic uptake tests earned out at
37°C showed that microspheres coated with any surfactant
cause a decrement in the phagocytosis in both the condi-
tions, i.e. either in the presence or absence of serum. How-
ever, the extent of decrease varied among the nature of the
surfactants, and in most instances, the presence of serum had
no influence on the phagocytosis when mi~rospheres were
coated with the same surfactant.' Microspheres from some
biodegradable substances such as copolymers of polylactic
acid and poly-glycolic acid [I] 5,I] 6], cross-linked potato
starch [I] 7], hydroxyethyl starch [I] 8], and cross linked
starch, dextran, lichenan and mannan are found to be success-
fully phagocytosed by macrophages [119].
Finally, we can conclude that despite the fact that most
of the important factors influencing the targeting of various
carriers to macrophages have been studied extensively, very
little attention has been paid to the factors relevant to drug
materials themselves such as molecular weight, position in
the particles, concentration, physicochemical parameters.
Much work remains to be done on the environmental factors
such as hydrogen ion concentration, polarity, ionic strength
and presence of enzymes. It can be envisaged that this may
require a lot more to decipher role of various yet unknown
factors in targeting of drugs to this important cell of the
immune system. It is quite heartening to note that a lot
many liposome-based fomlUlations have already been intro-
duced in the market [87], and some lipid based vehicles hav-
ing muramyl peptide have been successfully employed in
treatment of retractable melanoma and relapsed osteosarcoma
in human subjects [120-122]. However, no serious efforts
have been made to investigate the relevanceof tuftsin-based
formulations against treatment of various macrophage related
ailments. It would be imperative to emphasize, that the
magic peptide that has potential to establish itself as pana-
cea, ought to get due attention.
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